$ANIK (Anika Therapeutics Inc)

$ANIK {{ '2016-03-28T13:22:27+0000' | timeago}} • Announcement

Integrated orthopedic medicines company $ANIK said it received CE Mark approval for CINGAL as a medical device to treat pain associated with osteoarthritis of the knee. CINGAL is the first and only commercially-available combination viscosupplement, formulated with $ANIK's proprietary cross-linked sodium hyaluronate and triamcinolone hexacetonide.

$MRK {{ '2017-07-28T15:52:14+0000' | timeago}} • Announcement

Pharma segment, $MRK's only reportable segment and money-spinner, rose modestly to $8.76Bil. Growth was mainly due to new product launches offset by generic drug launches from competition and lower diabetes drug sales. Merck also narrowed and raised its 2017 revenue outlook to $39.4-40.4Bil, but reduced its 2017 GAAP EPS forecast to $1.60-1.72.

$SYK {{ '2017-07-28T15:37:01+0000' | timeago}} • Announcement

$SYK, which is seeing a steady growth in the surgical booms market, reported a 6.1% jump in revenue to $3Bil for the second quarter of 2017.  Stryker’s revenue from Neurotechnology rose 13% to $352MM.

$SYK {{ '2017-07-28T15:36:41+0000' | timeago}} • Announcement

Surgical equipment manufacturer $SYK posted a 2.9% increase in net earnings to $391MM for the second quarter of 2017, compared to a year ago period. Organic net sales growth for 2017 is expected to be in the range of 6.5-7.0% and adjusted EPS to be in the range of $6.45-6.55.

$MRK {{ '2017-07-28T15:26:51+0000' | timeago}} • Announcement

Pharma giant $MRK reported better-than-expected sales due to strong demand from its cancer drug KEYTRUDA. Sales for KEYTRUDA tripled to $881MM vs. $314MM in 2Q16. Drugmarker also disclosed that cyber-attack (June 27) had a dent on its operations. Magnitude of the disruption is yet to be ascertained, as $MRK tries to restore from the attack.

$MRK {{ '2017-07-28T13:05:50+0000' | timeago}} • Infographic

$MRK Merck Earnings AlphaGraphic: Q2 2017 Highlights

$ANIK {{ '2017-07-28T11:57:43+0000' | timeago}} • Announcement

$ANIK, an integrated orthopedic medicine company, has appointed Joseph Darling, an orthopedic and medical device veteran with broad commercial experience, as its President. For the past 15 years, company's CEO Dr Charles Sherwood served as President and plans to transition the role to Darling, while continuing as CEO.

$MRK {{ '2017-07-26T13:49:00+0000' | timeago}} • Announcement

$MRK's BoD declared a quarterly dividend of $0.47 per share of its common stock for 4Q17. The dividend will be paid on Oct. 6, 2017 to shareholders of record at the close of business on Sept. 15, 2017.

$MRK {{ '2017-07-25T17:08:10+0000' | timeago}} • Announcement

$MRK announced the presentation of results from the Drive-Ahead study, the second of two pivotal Phase 3 clinical trials evaluating the efficacy and safety of doravirine, the company's investigational, non-nucleoside reverse transcriptase inhibitor (NNRTI), for the treatment of HIV-1 infection.

$MRK {{ '2017-07-25T11:50:57+0000' | timeago}} • Announcement

$MRK said that its anti-programmed cell death protein 1 (PD1) drug Keytruda (pembrolizumab) failed to meet the primary endpoint in the Phase III KEYNOTE-040 trial for previously treated recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). When compared with standard treatment, Keytruda failed to improve the overall survival rate.

$ANIK {{ '2017-07-24T22:09:19+0000' | timeago}} • Announcement

$ANIK said regulatory authorities in India granted approval to MONOVISC, its single injection viscosupplement for the treatment of pain associated with osteoarthritis of all human synovial joints. $ANIK plans to expand MONOVISC into India, Australia, New Zealand and other international markets over the next 6-9 months.

$MRK {{ '2017-07-24T18:28:47+0000' | timeago}} • Announcement

$MRK today announced the US launch of RENFLEXIS, a biosimilar for Remicade, which was approved by FDA for all eligible indications. RENFLEXIS will have a wholesale acquisition cost of $753.39, which is a 35% discount compared to Remicade. Remicade was the fifth bestselling drug in the US in 2016 raking in $5.3Bil on an invoice price basis.

$TFX {{ '2017-07-24T12:12:24+0000' | timeago}} • Announcement

$TFX said its Arrow Seldinger Arterial Catheterization Device received market clearance from the U.S. Food and Drug Administration (FDA). The new Seldinger Arterial Catheterization Device is indicated for short-term use. $TFX expects to launch the Arrow Seldinger Arterial Catheterization Device in US this year.

$MRK {{ '2017-07-21T15:21:07+0000' | timeago}} • Announcement

President Donald Trump announced that pharma giants $MRK and $PFE are collaborating with Gorilla Glass manufacturer Corning ($GLW) for manufacturing a new glass (Valor Glass), which is superior and reliable for the delivery of injectable drugs. Corning is planning to initially invest $500MM creating 1,000 jobs at 3 facilities in US.

$MRK {{ '2017-07-20T14:29:27+0000' | timeago}} • Announcement

$MRK announced that the U.S. Food and Drug Administration (FDA) has granted tentative approval for its 100 units/mL insulin glargine injection, a follow-on biologic basal insulin in a pre-filled dosing device.

$HRC {{ '2017-07-19T14:11:03+0000' | timeago}} • Announcement

$HRC declared a dividend of $0.18 per share for 4Q17 payable on September 29, 2017, to shareholders of record as of September 15, 2017. The indicated annual dividend rate is $0.72 per share.

$ANIK {{ '2017-07-17T22:07:56+0000' | timeago}} • Announcement

$ANIK announced preliminary revenue for 2Q17. The company expects total revenue growth to be 23-26% YoY, including licensing, milestone and contract revenue of approx. $5MM as a result of the milestone payment associated with MONOVISC.

$ANIK {{ '2017-07-17T22:07:36+0000' | timeago}} • Announcement

$ANIK will receive a $5MM milestone payment under the terms of its license agreement with its US commercial partner. The milestone payment was triggered by MONOVISC achieving $100MM in US end-user sales within a consecutive 12-month period at the end of June 2017. The company will recognize this milestone payment as revenue in 2Q17.

$MRK {{ '2017-07-06T12:50:08+0000' | timeago}} • Announcement

Pharma company $MRK will present its HIV portfolio and pipeline at the 9th IAS Conference on HIV Science. The presentations include late-breaker abstracts from two phase-3 pivotal clinical trials and a phase-1 study of MK-8591, Merck’s investigational nucleoside reverse transcriptase translocation inhibitor in adult patients with HIV-1 infection.

$MRK {{ '2017-07-05T22:11:39+0000' | timeago}} • Announcement

$MRK said the US FDA has placed a clinical hold on KEYNOTE-183, KEYNOTE-185 and KEYNOTE-023, three combination studies of KEYTRUDA (pembrolizumab), the company’s anti-PD-1 therapy, in the blood cancer multiple myeloma. The FDA has determined that the risks of KEYTRUDA outweigh any potential benefit for patients with multiple myeloma.

$MRK {{ '2017-06-27T14:06:02+0000' | timeago}} • Announcement

$MRK provided update on Reveal outcomes study of anacetrapid. $MRK plans to review the results of the trial with external experts, and will consider whether to file new drug applications with the FDA and other regulatory agencies. The results will be presented at the European Society of Cardiology meeting on Aug. 29, 2017.

Recent Transcripts

MRK (Merck & Co. Inc.)
Friday, July 28 2017 - 12:00pm
SYK (Stryker Corporation)
Thursday, July 27 2017 - 8:30pm
ANIK (Anika Therapeutics Inc)
Thursday, July 27 2017 - 1:00pm
CRY (CryoLife Inc.)
Tuesday, July 25 2017 - 12:00pm
ONVO (Organovo Holdings, Inc.)
Wednesday, June 7 2017 - 9:00pm
PTN (Palatin Technologies Inc.)
Tuesday, May 16 2017 - 3:00pm
HAE (Haemonetics Corporation)
Monday, May 8 2017 - 12:00pm
SYN (Synthetic Biologics Inc.)
Thursday, May 4 2017 - 8:30pm
ANIK (Anika Therapeutics Inc)
Thursday, May 4 2017 - 1:00pm
TFX (Teleflex Incorporated)
Thursday, May 4 2017 - 12:00pm
IRIX (IRIDEX Corporation)
Wednesday, May 3 2017 - 9:30pm
GMED (Globus Medical, Inc.)
Wednesday, May 3 2017 - 9:30pm
STAA (STAAR Surgical Company)
Wednesday, May 3 2017 - 8:30pm
MRK (Merck & Co. Inc.)
Tuesday, May 2 2017 - 12:00pm
HRC (Hill-Rom Holdings, Inc.)
Friday, April 28 2017 - 12:30pm
RMD (ResMed Inc.)
Thursday, April 27 2017 - 8:30pm
CRY (CryoLife Inc.)
Thursday, April 27 2017 - 12:00pm
SYK (Stryker Corporation)
Tuesday, April 25 2017 - 8:30pm
IRIX (IRIDEX Corporation)
Wednesday, March 8 2017 - 10:00pm
STAA (STAAR Surgical Company)
Thursday, March 2 2017 - 9:30pm

AlphaGraphics you may like